Repare Therapeutics’ Post

View organization page for Repare Therapeutics, graphic

14,311 followers

We are thrilled to share that the FDA granted Fast Track designation to the lunresertib-camonsertib combination for the treatment of platinum-resistant ovarian cancer. Learn more here: https://lnkd.in/e5n8Acxn #precisiononcology #syntheticlethality #fasttrackdesignation #ovariancancer

  • No alternative text description for this image
Maria Koehler MD PhD

Chief Medical Officer at Repare Therapeutics

1mo

So satisfying to work with a great team that delivers great medicines to offer promise to patients- the promise will soon become a reality …..that’s why we all are doing this work = pleasure

Gagan Kukreja

Associate Director, Medicinal Chemistry, SynVent IDD, Syngene

1mo

Really a ground breaking discovery. And probably this is just a start. Besides ATR, I am sure lunresertib (RP-6306) first-in-class, oral PKMYT1 inhibitor will do equally well or even better in the ongoing Phase 1 in combination with Wee1 inhibitor from Debiopharm. Again credit goes to Repare! With efficacy granted, what remains to be seen is whether FDA would grant Fast Track designation to this PKMYT1/WEE1 combination, when both of RP-6306 and Debio-0123 are still in Phase 1 and Phase 1/2 clinical trials as standalone therapies with no prior drug approvals coming from either of the drug targets.

Wonderful news. Congratulations!

Like
Reply
Martin Højgaard

Oncologist, Phase 1 Unit, Department of Oncology at Rigshopitalet

1mo

Great news, well deserved

Patrick Montpetit

Member Board of Directors | Chartered Professional Accountant (CPA Canada)

1mo

Great news. Well done team Repare

Like
Reply
Jeff Bockman

EVP & Expert Advisor, Oncology, Head Center of Excellence, Lumanity, Scientific/Clinical/Strategic Advisory Boards at ImmunOS, hC Bioscience, Valo Therapeutics, Pearl Bio, Skipper BioMed

1mo

Fantastic work, kudos to the Repare team.

Like
Reply
Oksana Bovt

CEO | Fundraising marketing for life sciences | Theoria Creative

1mo

This is a great achievement Steve Forte, Lloyd Mitchell Segal and Repare Therapeutics!

Like
Reply
Demetra Georgiopoulos

Biopharmaceutical Consultant, New Product Pipeline, Portfolio & Commercial Strategy

1mo

Amazing news!

Like
Reply
Tracy Flack Tyler, MBA

Founder and Managing Principal, Strategies for Success Int'l

1mo

Fantastic news, Lloyd! Wishing you continued success!

Like
Reply
Rafi Hofstein

life science executive

1mo

Sensational!

Like
Reply
See more comments

To view or add a comment, sign in

Explore topics